Associated Papers
A single nucleotide polymorphism in the TCL1A promoter is not protective in patients with germ line RUNX1-FPD.
Kajdic A et al.
Blood Neoplasia, 2025
41127867 (PubMed )
Supplement: BNEO_NEO-2025-000690-mmc1.pdf
Impact of Carrying DNMT3A or TET2 Mutations on Plaque Characteristics and Prognosis in Patients With STEMI Based on OCT.
Sun Q et al.
Circulation. Cardiovascular Imaging, 2025
40755316 (PubMed )
Supplement: circcvim-2024-017915-s03.pdf
Genomic characterization of AML with aberrations of chromosome 7: a multinational cohort of 519 patients.
Halik A et al.
Journal of Hematology & Oncology, 2024
39160538 (PubMed )
Supplement: 13045_2024_1590_MOESM1_ESM.xlsx › Suppl._Dataset_4_TS_SNV
Genomic landscape of patients with germline RUNX1 variants and familial platelet disorder with myeloid malignancy.
Yu K et al.
Blood Advances, 2024
38019014 (PubMed )
Supplement: BLOODA_ADV-2023-011165-mmc2.xlsx › Somatic_Mutations
Postazacitidine clone size predicts long-term outcome of patients with myelodysplastic syndromes and related myeloid neoplasms.
Nannya Y et al.
Blood Advances, 2023
36989067 (PubMed )
Supplement: BLOODA_ADV-2022-009564-mmc2.xlsx › SuppTable2
Compartment-specific mutational landscape of clonal hematopoiesis.
Hartmann L et al.
Leukemia, 2022
36131041 (PubMed )
Supplement: 41375_2022_1700_MOESM1_ESM.pdf
TET2-Driven Clonal Hematopoiesis and Response to Canakinumab: An Exploratory Analysis of the CANTOS Randomized Clinical Trial.
Svensson EC et al.
Jama Cardiology, 2022
Mutation of ten-eleven translocation-2 is associated with increased risk of autoimmune disease in patients with myelodysplastic syndrome.
Oh YJ et al.
The Korean Journal of Internal Medicine, 2020
Next-Generation Sequencing Improves Diagnosis, Prognosis and Clinical Management of Myeloid Neoplasms.
Carbonell D et al.
Cancers, 2019
31540291 (PubMed )
Supplement: cancers-11-01364-s001.zip › cancers-588721-SI.pdf
Convenient expression, purification and quantitative liquid chromatography-tandem mass spectrometry-based analysis of TET2 5-methylcytosine demethylase.
Jaiswal M et al.
Protein Expression and Purification, 2017
The Interlaboratory RObustness of Next-generation sequencing (IRON) study: a deep sequencing investigation of TET2, CBL and KRAS mutations by an international consortium involving 10 laboratories.
Kohlmann A et al.
Leukemia, 2011
Next-generation sequencing technology reveals a characteristic pattern of molecular mutations in 72.8% of chronic myelomonocytic leukemia by detecting frequent alterations in TET2, CBL, RAS, and RUNX1.
Kohlmann A et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology, 2010
Select a paper to view details